Guangzhou LBP Medicine Science & Technology Co Ltd (688393) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guangzhou LBP Medicine Science & Technology Co Ltd (688393) has a cash flow conversion efficiency ratio of 0.024x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥29.17 Million ≈ $4.27 Million USD) by net assets (CN¥1.20 Billion ≈ $175.41 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 688393 stock market capitalisation for the company's overall valuation and market capitalisation.
Guangzhou LBP Medicine Science & Technology Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Guangzhou LBP Medicine Science & Technology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Guangzhou LBP Medicine Science & Technology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guangzhou LBP Medicine Science & Technology Co Ltd ranked by their cash flow conversion efficiency. Explore how high is Guangzhou LBP Medicine Science & Technol's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eaton Vance Senior Floating Rate Closed Fund
NYSE:EFR
|
0.098x |
|
Sappe Public Company Limited
BK:SAPPE
|
0.070x |
|
Armata Pharmaceuticals Inc
NYSE MKT:ARMP
|
0.031x |
|
Nalwa Sons Investments Limited
NSE:NSIL
|
0.003x |
|
Sinomach General Machinery Science Technology Co Ltd
SHG:600444
|
0.093x |
|
Zhejiang Dilong New Material Co Ltd
SHE:002247
|
0.021x |
|
Echoiq Ltd
AU:EIQ
|
-0.300x |
|
Hengxin Mobile Business
SHE:300081
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Guangzhou LBP Medicine Science & Technology Co Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Guangzhou LBP Medicine Science & Technology Co Ltd from 2011 to 2024. View current stock price of Guangzhou LBP Medicine Science & Technol for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.23 Billion ≈ $180.24 Million |
CN¥3.54 Million ≈ $518.49K |
0.003x | -79.19% |
| 2023-12-31 | CN¥1.24 Billion ≈ $181.20 Million |
CN¥17.12 Million ≈ $2.51 Million |
0.014x | +73.94% |
| 2022-12-31 | CN¥1.22 Billion ≈ $178.87 Million |
CN¥9.72 Million ≈ $1.42 Million |
0.008x | -83.87% |
| 2021-12-31 | CN¥1.21 Billion ≈ $177.02 Million |
CN¥59.61 Million ≈ $8.72 Million |
0.049x | -37.07% |
| 2020-12-31 | CN¥1.17 Billion ≈ $170.85 Million |
CN¥91.43 Million ≈ $13.38 Million |
0.078x | -61.20% |
| 2019-12-31 | CN¥444.63 Million ≈ $65.06 Million |
CN¥89.74 Million ≈ $13.13 Million |
0.202x | +20.24% |
| 2018-12-31 | CN¥389.32 Million ≈ $56.97 Million |
CN¥65.35 Million ≈ $9.56 Million |
0.168x | -30.73% |
| 2017-12-31 | CN¥346.28 Million ≈ $50.67 Million |
CN¥83.92 Million ≈ $12.28 Million |
0.242x | +79.32% |
| 2016-12-31 | CN¥320.94 Million ≈ $46.96 Million |
CN¥43.37 Million ≈ $6.35 Million |
0.135x | +4270.59% |
| 2013-12-31 | CN¥215.00 Million ≈ $31.46 Million |
CN¥-696.70K ≈ $-101.95K |
-0.003x | -111.61% |
| 2012-12-31 | CN¥173.32 Million ≈ $25.36 Million |
CN¥4.84 Million ≈ $707.67K |
0.028x | +108.80% |
| 2011-12-31 | CN¥48.09 Million ≈ $7.04 Million |
CN¥-15.24 Million ≈ $-2.23 Million |
-0.317x | -- |
About Guangzhou LBP Medicine Science & Technology Co Ltd
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China and internationally. The company offers pathological diagnostic reagents and ancillary equipment that consists of liquid-based cytology products, including liquid-based cytology production machines and automatic sample transfer machines; polymerase… Read more